OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCXFree Report) in a report issued on Friday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.06.

Read Our Latest Research Report on OncoCyte

OncoCyte Stock Performance

Shares of NASDAQ:OCX traded down $0.03 during trading on Friday, reaching $2.83. 6,731 shares of the company traded hands, compared to its average volume of 35,684. The company’s 50 day moving average is $3.05 and its two-hundred day moving average is $2.97. OncoCyte has a 52 week low of $2.29 and a 52 week high of $4.34.

OncoCyte (NASDAQ:OCXGet Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. The company had revenue of $0.10 million during the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

Insiders Place Their Bets

In other OncoCyte news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Andrea S. James acquired 33,670 shares of OncoCyte stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, with a total value of $99,999.90. Following the transaction, the chief financial officer now owns 33,670 shares of the company’s stock, valued at approximately $99,999.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now directly owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.58% of the company’s stock.

OncoCyte Company Profile

(Get Free Report)

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.

Featured Stories

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.